NAD on One-A-Day
This article was originally published in The Tan Sheet
Bayer HealthCare should discontinue advertising claims stating that men can reduce their risk of prostate cancer by taking One-A-Day Men's Health Formula, the watchdog group concludes in a recent Case Report. Although Bayer cited Harvard Medical School studies linking lycopene to prostate health, ad claims conveyed a message that was "much broader than the evidence could support," NAD maintains. The ad depicts a fire chief who advises his coworkers to switch to One-A-Day Men's when he learns that "one in three men face prostate cancer." Bayer provided reasonable scientific evidence to support the link between lycopene and prostate health, NAD says, but the ad's "tone of concern" and backdrop "make it reasonable for consumers to take away a message that taking One-A-Day has a cancer preventive effect because it contains lycopene"...
You may also be interested in...
Nearly half of the National Advertising Division cases involving the OTC drug, dietary supplement and oral care markets thus far in 2004 were initiated by the watchdog group, and not brought forward by a competing company
AstraZeneca has sent a legal notice to Indian partner Serum Institute for non-delivery of COVID-19 vaccines. Will this and the entry of a new challenger, Sputnik V, in the Indian market affect Serum’s fortunes? Will the EMA and MHRA announcement on clotting incidents related to the AZ vaccine shrink demand for the partnered vaccine?
As medical organizations such as the Veterans Health Administration and Mayo Clinic are positioning themselves to become medical device manufacturers using 3D printing technologies, it opens challenges and opportunities. See what Mayo Clinic’s Sean McEligot said about it here.